Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13568
UPID:
IRF5_HUMAN
Alternative names:
-
Alternative UPACC:
Q13568; A4D1J8; A8DUA8; A8DUA9; E7EQ16; E7EW54; Q1A7B4; Q64GA9; Q64GB1; Q64GB2; Q6RCM8; Q9BQF0
Background:
Interferon regulatory factor 5 (IRF5) is pivotal in innate immunity, activating type I interferon and inflammatory cytokines upon detection of pathogens. It binds to an interferon-stimulated response element, regulating genes critical for immune response. IRF5's role extends to modulating the IFN response during viral infections, including SARS-CoV-2.
Therapeutic significance:
IRF5's involvement in diseases like Inflammatory bowel disease 14, Systemic lupus erythematosus 10, and Rheumatoid arthritis underscores its therapeutic potential. Targeting IRF5 could lead to innovative treatments for these autoimmune and inflammatory conditions, offering hope for patients seeking alternatives to current therapies.